Development and validation of multivariable prediction models of remission, recovery, and quality of life outcomes in people with first episode psychosis: a machine learning approach.


Journal

The Lancet. Digital health
ISSN: 2589-7500
Titre abrégé: Lancet Digit Health
Pays: England
ID NLM: 101751302

Informations de publication

Date de publication:
10 2019
Historique:
received: 09 08 2019
accepted: 12 08 2019
entrez: 16 12 2020
pubmed: 1 10 2019
medline: 28 1 2021
Statut: ppublish

Résumé

Outcomes for people with first-episode psychosis are highly heterogeneous. Few reliable validated methods are available to predict the outcome for individual patients in the first clinical contact. In this study, we aimed to build multivariable prediction models of 1-year remission and recovery outcomes using baseline clinical variables in people with first-episode psychosis. In this machine learning approach, we applied supervised machine learning, using regularised regression and nested leave-one-site-out cross-validation, to baseline clinical data from the English Evaluating the Development and Impact of Early Intervention Services (EDEN) study (n=1027), to develop and internally validate prediction models at 1-year follow-up. We assessed four binary outcomes that were recorded at 1 year: symptom remission, social recovery, vocational recovery, and quality of life (QoL). We externally validated the prediction models by selecting from the top predictor variables identified in the internal validation models the variables shared with the external validation datasets comprised of two Scottish longitudinal cohort studies (n=162) and the OPUS trial, a randomised controlled trial of specialised assertive intervention versus standard treatment (n=578). The performance of prediction models was robust for the four 1-year outcomes of symptom remission (area under the receiver operating characteristic curve [AUC] 0·703, 95% CI 0·664-0·742), social recovery (0·731, 0·697-0·765), vocational recovery (0·736, 0·702-0·771), and QoL (0·704, 0·667-0·742; p<0·0001 for all outcomes), on internal validation. We externally validated the outcomes of symptom remission (AUC 0·680, 95% CI 0·587-0·773), vocational recovery (0·867, 0·805-0·930), and QoL (0·679, 0·522-0·836) in the Scottish datasets, and symptom remission (0·616, 0·553-0·679), social recovery (0·573, 0·504-0·643), vocational recovery (0·660, 0·610-0·710), and QoL (0·556, 0·481-0·631) in the OPUS dataset. In our machine learning analysis, we showed that prediction models can reliably and prospectively identify poor remission and recovery outcomes at 1 year for patients with first-episode psychosis using baseline clinical variables at first clinical contact. Lundbeck Foundation.

Sections du résumé

BACKGROUND
Outcomes for people with first-episode psychosis are highly heterogeneous. Few reliable validated methods are available to predict the outcome for individual patients in the first clinical contact. In this study, we aimed to build multivariable prediction models of 1-year remission and recovery outcomes using baseline clinical variables in people with first-episode psychosis.
METHODS
In this machine learning approach, we applied supervised machine learning, using regularised regression and nested leave-one-site-out cross-validation, to baseline clinical data from the English Evaluating the Development and Impact of Early Intervention Services (EDEN) study (n=1027), to develop and internally validate prediction models at 1-year follow-up. We assessed four binary outcomes that were recorded at 1 year: symptom remission, social recovery, vocational recovery, and quality of life (QoL). We externally validated the prediction models by selecting from the top predictor variables identified in the internal validation models the variables shared with the external validation datasets comprised of two Scottish longitudinal cohort studies (n=162) and the OPUS trial, a randomised controlled trial of specialised assertive intervention versus standard treatment (n=578).
FINDINGS
The performance of prediction models was robust for the four 1-year outcomes of symptom remission (area under the receiver operating characteristic curve [AUC] 0·703, 95% CI 0·664-0·742), social recovery (0·731, 0·697-0·765), vocational recovery (0·736, 0·702-0·771), and QoL (0·704, 0·667-0·742; p<0·0001 for all outcomes), on internal validation. We externally validated the outcomes of symptom remission (AUC 0·680, 95% CI 0·587-0·773), vocational recovery (0·867, 0·805-0·930), and QoL (0·679, 0·522-0·836) in the Scottish datasets, and symptom remission (0·616, 0·553-0·679), social recovery (0·573, 0·504-0·643), vocational recovery (0·660, 0·610-0·710), and QoL (0·556, 0·481-0·631) in the OPUS dataset.
INTERPRETATION
In our machine learning analysis, we showed that prediction models can reliably and prospectively identify poor remission and recovery outcomes at 1 year for patients with first-episode psychosis using baseline clinical variables at first clinical contact.
FUNDING
Lundbeck Foundation.

Identifiants

pubmed: 33323250
pii: S2589-7500(19)30121-9
doi: 10.1016/S2589-7500(19)30121-9
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e261-e270

Subventions

Organisme : Wellcome Trust
ID : 104025/Z/14/Z
Pays : United Kingdom
Organisme : Department of Health
ID : RDD/ARF2
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : CAF/19/04
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : CZH/4/295
Pays : United Kingdom
Organisme : Department of Health
ID : RP-­PG-­0109-10074
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : CZH/3/5
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Samuel P Leighton (SP)

Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Rachel Upthegrove (R)

Institute for Mental Health, University of Birmingham, Birmingham, UK.

Rajeev Krishnadas (R)

Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK.

Michael E Benros (ME)

Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

Matthew R Broome (MR)

Institute for Mental Health, University of Birmingham, Birmingham, UK.

Georgios V Gkoutos (GV)

Institute of Cancer and Genomics, University of Birmingham, Birmingham, UK; Institute of Translational Medicine, University of Birmingham, Birmingham, UK; Health Data Research UK Midlands, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Peter F Liddle (PF)

Institute of Mental Health, University of Nottingham, Nottingham, UK.

Swaran P Singh (SP)

Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, UK.

Linda Everard (L)

The Barberry, Birmingham, UK.

Peter B Jones (PB)

Wolfson College, University of Cambridge, Cambridge, UK.

David Fowler (D)

School of Psychology, University of Sussex, Brighton, UK.

Vimal Sharma (V)

Department of Health and Social Care, University of Chester, Chester, UK.

Nicholas Freemantle (N)

Comprehensive Trials Unit, University College London, London, UK.

Rune H B Christensen (RHB)

Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

Nikolai Albert (N)

Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

Merete Nordentoft (M)

Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Matthias Schwannauer (M)

School of Health in Social Science, Clinical Psychology, University of Edinburgh, Edinburgh, UK.

Jonathan Cavanagh (J)

Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Andrew I Gumley (AI)

Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Max Birchwood (M)

Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, UK.

Pavan K Mallikarjun (PK)

Institute for Mental Health, University of Birmingham, Birmingham, UK. Electronic address: p.mallikarjun@bham.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH